Yoshiaki Ohtsu

List of Publications by Year in Descending Order

23 papers	362 citations	8 h-index	18 g-index
25 ext. papers	426 ext. citations	3 avg, IF	3.02 L-index

#	Paper	IF	Citations
23	Highlights of the 12th Japan Bioanalysis Forum Symposium. *Bioanalysis*, **2021**, 13, 1653-1657	2.1	
22	Analytical method validation for biomarkers as a drug development tool: points to consider. *Bioanalysis*, **2021**, 13, 1379-1389	2.1	3
21	Intersubject and Intrasubject Variability of Potential Plasma and Urine Metabolite and Protein Biomarkers in Healthy Human Volunteers. *Clinical Pharmacology and Therapeutics*, **2020**, 107, 397-405	6.1	1
20	Biomarker assay validation for clinical trials: a questionnaire survey to pharmaceutical companies in Japan. *Bioanalysis*, **2019**, 11, 55-60	2.1	3
19	An Open-Label, Single-Dose, Human Mass Balance Study of Amenamevir in Healthy Male Adults. *Clinical Pharmacology in Drug Development*, **2019**, 8, 595-602	2.3	1
18	Absorption, Distribution, Metabolism, and Excretion of the Novel Helicase-Primase Inhibitor, Amenamevir (ASP2151), in Rodents. *European Journal of Drug Metabolism and Pharmacokinetics*, **2018**, 43, 693-706	2.7	5
17	Bioanalytical Quantification of Therapeutic Antibodies by Liquid Chromatography/mass Spectrometry. *Chromatography*, **2018**, 39, 7-19	1.2	1
16	Quantification of ASP2151 in Human Plasma and Urine: A Pitfall Associated with Supersaturation of Analyte in Urine. *Chromatographia*, **2017**, 80, 217-227	2.1	7
15	Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults. *Advances in Therapy*, **2017**, 34, 2466-2480	4.1	7
14	Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies. *Advances in Therapy*, **2017**, 34, 2625-2637	4.1	13
13	Absorption, Distribution, Metabolism, and Excretion of the Androgen Receptor Inhibitor Enzalutamide in Rats and Dogs. *European Journal of Drug Metabolism and Pharmacokinetics*, **2017**, 42, 611-626	2.7	7
12	Incurred sample stability of ASP3258 in the presence of its acyl glucuronide. *Journal of Applied Bioanalysis*, **2017**, 3, 34-42	1.3	3
11	Clinical Pharmacokinetic Studies of Enzalutamide. *Clinical Pharmacokinetics*, **2015**, 54, 1043-55	6.2	83
10	Regulated bioanalysis of conformers - A case study with ASP2151 in dog plasma and urine. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2015**, 997, 56-63	3.2	3
9	Determination of ASP3258, a novel phosphodiesterase type 4 inhibitor, in rat plasma by high-performance liquid chromatography with fluorescence detection and its application to pharmacokinetic study. *Biomedical Chromatography*, **2015**, 29, 161-3	1.7	2
8	Absorption, distribution, metabolism and excretion of novel phosphodiesterase type 4 inhibitor ASP3258 in rats. *Biopharmaceutics and Drug Disposition*, **2015**, 36, 34-48	1.7	1
7	Determination of the Androgen Receptor Inhibitor Enzalutamide and its Metabolites in Animal Plasma and Brain Homogenates Using LC-MS/MS and its Application to Pharmacokinetic Studies. *Chromatography*, **2015**, 36, 115-122	1.2	7

6	Pharmacokinetic Drug Interaction Studies with Enzalutamide. *Clinical Pharmacokinetics*, **2015**, 54, 1057-69	6.2	88
5	Stability: recommendation for best practices and harmonization from the Global Bioanalysis Consortium Harmonization Team. *AAPS Journal*, **2014**, 16, 392-9	3.7	39
4	Validation of a method for quantifying enzalutamide and its major metabolites in human plasma by LC-MS/MS. *Bioanalysis*, **2014**, 6, 737-44	2.1	27
3	Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 1339-46	5.9	23
2	Therapeutic potential of ASP3258, a selective phosphodiesterase 4 inhibitor, on chronic eosinophilic airway inflammation. *Pharmacology*, **2012**, 90, 223-32	2.3	10
1	ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity. *International Immunopharmacology*, **2011**, 11, 732-9	5.8	25